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Abstract
CD62L/L-selectin is a marker found on naı ¨ve T cells and further distinguishes central memory (Tcm, CD62L+) from effector
memory (Tem, CD62L2) T cells. The regulation of CD62L plays a pivotal role in controlling the traffic of T lymphocytes to
and from peripheral lymph nodes. CD62L is shed from the cell membrane following T cell activation, however, the
physiological significance of this event remains to be elucidated. In this study, we utilized in vitro generated anti-tumor
antigen T cells and melanoma lines as a model to evaluate the dynamics of CD62L shedding and expression of CD107a as a
marker of lytic activity. Upon encounter, with matched tumor lines, antigen reactive T cells rapidly lose CD62L expression
and this was associated with the acquisition of CD107a. By CD62L ELISA, we confirmed that this transition was mediated by
the shedding of CD62L when T cells encountered specific tumor antigen. The introduction of a shedding resistant mutant of
CD62L into the tumor antigen-reactive T cell line JKF6 impaired CD107a acquisition following antigen recognition and this
was correlated with decreased lytic activity as measured by
51Cr release assays. The linkage of the shedding of CD62L from
the surface of anti-tumor T cells and acquisition of lytic activity, suggests a new function for CD62L in T cell effector
functions and anti-tumor activity.
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Introduction
The trafficking of leukocytes from the peripheral blood to the
surrounding tissue is pivotal for inflammatory responses and is
tightly regulated by cell adhesion molecules on T lymphocytes and
endothelial cells [1]. The selectins are a family of cell adhesion
molecules including E-selectin, P-selectin and L-selectin, which
coordinately contribute to leukocyte tethering and rolling along
the luminal surface of venules [2,3]. L-selectin, also known as
CD62L, is a cell adhesion molecule found on leukocytes including
lymphocytes, neutrophils, monocytes, eosinophils, and hemato-
poietic progenitor cells. When a CD62L+ T cell enters a lymph
node it can become activated by antigen presenting cells (APC)
and upon activation, CD62L is cleaved at K283-S284 by a
disintegrin and metalloprotease ADAM17 [4,5,6]. Following the
shedding of CD62L from antigen-activated T cells in lymph
nodes, T cells can reenter the circulation where they can exert
their helper or effector functions [7].
A CD62L knockout mouse model indicates that CD62L plays
an essential role in lymphocyte homing to lymphoid tissues and
sites of inflammation [8]. However, transgenic mice over-
expressing a shedding resistant CD62L demonstrated that
shedding of CD62L is not required for memory T cell
recirculation and homing to peripheral lymph nodes or migration
to sites of infection, however, the ability to clear virus was
significantly compromised [9]. These authors argued that the
delayed viral clearance in this mouse model likely resulted from
improper adhesion and migration of lymphocytes [9].
In T cell mediated immune responses, following encounter with
pathogens T cells experience an expansion and then a contraction
phase, which leads to a long-lived pool of memory cells. Memory
T cells can be further classified by their differentiation markers
(CD62L and CCR7) or the release of cytokines (IL2 and IFN-c)a s
central memory cells (Tcm, CD62L+) and effector memory (Tem,
CD62L2) [10,11,12,13]. While there exists heterogeneity for
CCR7 [14] marker expression in memory T cells [15,16,17],
CD62L is more uniformly expressed and a reliable surface protein
marker to distinguish between Tcm and Tem. Memory T cell
subsets have distinct migratory patterns after encountering antigen
and activation. Tem cells primarily migrate to non-lymphoid
tissues and inflammation sites, whereas Tcm cells have the
capacity to migrate to peripheral lymph nodes [18,19]. Tcm cells
display a capacity for self-renewal, and have been reported in
animal studies to lead to sustained engraftment and potent anti-
tumor efficacy in adoptive immunotherapy [20,21]. Tem have a
lower proliferative capacity [22,23], but have a pronounced
capacity for immediate effector function mediated by the pre-
expression of granzyme B and perforin within intracellular
cytotoxic granules, a type of secretory lysosome [10,24,25,26].
These cytoxic granules are often studied by the expression of
surrogate marker proteins know as lysosomal-associated mem-
brane proteins. Lysosomal-associated membrane proteins CD107a
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and predominantly expressed intracellularly in the lysosomal/
endosomal membrane in nearly all cells, yet their exact function
remains unknown [27]. In T cells and NK cells they are found on
the intracellular cytotoxic granules, but not on the cell surface.
When the cytotoxic granules transiently traffic to the cell surface
during the formation of the immunological synapse and
degranulation, this results in the expression of CD107 on the cell
surface [26,28,29]. CD107a in particular has been described as a
marker of NK and CD8+ T-cell degranulation following
stimulation [30,31,32].
In this study, we used human PBL or purified CD8+ T cells
genetically engineered with an anti-tumor TCR [33,34,35] as a
model to evaluate the dynamics of CD62L regulation after
encountering tumor antigen. Using this model, we illustrated, for
the first time, that the shedding of CD62L was tumor antigen
specific, and coupled to the appearance of a degranulation marker
CD107a [31]. Interestingly, the relationship of CD62L shedding
and formation of CD107a was reciprocal, i.e., introduction of
shedding resistant mutant of CD62L onto surface of CD8+ T cells
adversely affected CD107a cell surface expression after encoun-
tering tumor antigen.
Materials and Methods
Cell culture
All PBL and melanoma cell lines used in this study were
obtained under written informed consent from healthy donors and
metastatic melanoma patients seeking treatments at Surgery
Branch, National Cancer Institute (NCI). All protocols were
reviewed and approved by the Institutional Review Board of the
National Cancer Institute, Bethesda, MD. Briefly, PBL were
collected by leukapheresis, and lymphocytes were separated by
Ficoll/Hypaque cushion centrifugation, washed in HBSS and
resuspended at a concentration of 1610
6/ml in AIM-V medium
(Invitrogen, Carlsbad, CA) supplemented with 300 IU/ml IL-2
(Chiron, Emmerville, CA) and 5% heat-inactivated human AB
serum (Valley Biomedical, Winchester, VA). Melanoma cell lines
were produced at the Surgery Branch NCI from patient material
obtained as described above and included MART-1 positive HLA-
A*0201
+ 624, 526 and one MART-1 negative HLA-A*0201
2 line
938 (all lines available upon request). 293T (ATCC, Manassas,
VA) cells were cultured in DMEM supplemented with 10% FCS,
100 U/ml penicillin/streptomycin, 2 mM L-glutamine, 20 mM2 -
mercaptoenthanol and 25 mM HEPES buffer solution (Invitro-
gen). JKF6 is a long-term cultured tumor infiltrated lymphocytes
(TIL) from melanoma patient maintained at Surgery Branch NCI.
All cell lines were cultured at 37uC in a 5% CO2 humidified
incubator.
Vector construction, preparation, and transduction
All lentiviral constructs utilized were derived from
pRRLSIN.cPPT.MSCV/GFP.wPRE harboring a green fluores-
cent protein (GFP) gene driven by the murine stem cell virus
(MSCV) U3 promoter [36], where the woodchuck hepatitis
response element (wPRE) was replaced with the truncated form,
oPRE as previously described [37] (vector termed
pLVV.GFP.oPRE). A lentiviral vector expressing an anti-
MART-1 TCR was based on the previously reported [38] vector
and is termed pLVV.coDMF5.oPRE. The human CD62L gene
(GenBank accession: AJ246000) was isolated from total RNA of in
vitro cultured PBLs by reverse-transcription-PCR using primers,
59-ggtacctgccggcgcgccgccgccatgggcatatttccatggaaatgtcagagc, and
39- gccgtcgacttaatatgggtcattcatacttctcttg. The PCR products were
purified and digested with Asc I and Sal I and ligated into
corresponding sites of pLLV.GFP.oPRE, to produce
pLVV.hCD62L.oPRE. The shedding resistant mutant of human
CD62L dK-S [4] was made with primers (59-cctagtccaatatgtcaaat-
gattaaggagggt, 39-atcaccctccttaatcatttgacatattggact) by site-direct-
ed mutagenesis kit (Stratagene, La Jolla, CA). All the constructs
are confirmed by restriction enzyme digestion and DNA
sequencing.
The production of lentiviral vector supernatants has been
previously described in detail [34,38,39]. Viral vector particle
concentration was estimated using a p24 ELISA (ZeptoMetrix,
Buffalo, NY) and was either used directly or stored at 280uC.
PBLs were transduced with the vector by spinoculation method
using 6-well culture plates. Briefly, 10
6 PBLs were washed twice
with PBS and pre-incubated with Dynal anti-CD3/CD28 beads
(Invitrogen, Carlsbad, CA) (cells to beads ratio 1:2) for 10 min at
room temperature and followed by overnight incubation. Next
day, 5 ml vector plus 1 ml AIM-V (with 10% FBS, IL-2 300 IU/
ml) were applied in the presence of 10 mg/ml protamine sulfate,
and the plates were centrifuged at 1000 g, 32uC for 2 h. Six hours
posttransduction, the cells were transferred to 75 CM
2 flasks for
continued culture in AIM-V containing 5% human serum,
300 IU/ml IL-2. Transduction of CD8+ T cells was accomplished
using OKT3-coated plates as previously described in detail [40].
FACS analysis and sorting
Cell surface expression of CD3, CD8, CD62L, CD107a and
CD45RO was measured using fluorescein isothiocyanate (FITC),
allophycocyanin (APC), phycoerythrin (PE), PE-Cy7, and APC-
Cy7-conjugated antibodies (BD Biosciences, San Jose, CA).
Custom designed MART-1: 27–35 tetramer was used (iTAg
MHC Tetramer, Beckman Coulter, Fullerton, CA), to detect TCR
gene-transduced cells. For live cell staining, cells were washed with
FACS buffer (PBS containing 2% FBS), and antibodies described
above were added directly into cells (10
6/ml) followed by 30 min
incubation at 4uC, the cells were washed twice with FACS buffer.
To gate out of dead cells, propidium iodide (Sigma-Aldrich, Saint
Louis, MO) in PBS was added to samples in a final concentration
5 mg/ml before FACS analysis. Interferon-gamma (IFN-c) was
measured using intracellular staining kit with reagents and
protocols as directed by the manufacturer (BD Biosciences).
Briefly, cells were resuspended in fixation/permeabilization
solution for 20 min at 4uC, then washed the cells twice using
perm/wash buffer followed by the addition of fluorochrome-
conjugated antibodies followed by 30 min incubation at 4uC. No
propidium iodide staining was performed for samples subject to
intracellular staining. Immunofluorescence staining was analyzed
as the relative log fluorescence of live cells, determined using a
FACscan flow cytometer (BD Biosciences). A combination of
forward angle light scatter and propidium iodide staining was used
to gate out the dead cells, and 1610
5 cells were analyzed. FACS
analysis was performed by the staff of the FACS core facility at
Surgery Branch/National Cancer Institute, Bethesda MD. Six-
color analysis was carried out on a Canto I or Canto II instrument
(BD Biosciences) with automatic compensation. Cultured T cells
were sorted using a FACSAria cell sorter (BD Biosciences). Briefly,
T cells were labeled with CD62L, CD45RO and CD8, subsets of
CD62L+/CD45RO+ and CD62L2/CD45RO+ were sorted.
FACS data was analyzed using FlowJo 8.1.1 software (FlowJo,
Ashland, OR).
Purification of CD8 T cells and CD62L positive cells
CD8+ and CD62L+ Microbeads (Miltenyi Biotec) were used for
purification of CD8+ T cells from PBMCs and CD62L+ TIL from
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the manufacturer.
Measurement of lymphocyte reactivity
The ability of transduced JKF6 to lyse HLA-A2+/MART-1
melanoma cells was evaluated using a
51Cr assay as described [41].
Briefly, 10
6 tumor cells were labeled for 1 h at 37uC with 100 mCi
of
51Cr (Amersham Biosciences, Pittsburgh, PA) in 2 ml of media.
Labeled target cells (2610
3) were co-cultured with effector cells at
the ratios indicated in the figures for 4 h at 37uC in 0.15 ml of
complete medium. Harvested supernatants were counted using a
MicroBeta TriLux instrument (Perkin Elmer, Waltham, MA).
Each data point was determined as the mean of quadruplicate
wells. The percentage of specific lysis was calculated as indicated in
figure legend. Determination of the amount of CD62L shedding
was performed as follows. The central memory enriched CD8+ T
cells expressing anti-MART-1 TCR were co-cultured with
melanoma lines (1610
6 each) in 14 ml round-bottom polypropyl-
ene tubes for 4 h (volume,1 ml). Cells were centrifuged (8006g
10 min) and supernatant were collected, and the cell pellet was
lysed using RIPA Buffer. The amount of CD62L in supernatant
and in cell lysates was determined by ELISA (R&D Systems,
Minneapolis, MN).
Results
The loss of CD62L is tumor antigen specific and is
associated with CD107a assembly
Using lentiviral vector transduction to introduce a tumor
antigen-specific TCR into human open repertoire T cells readily
generates anti-tumor T cells that have the potential for use in
adoptive immunotherapy [34,38]. As previously reported, the bulk
of these short-term cultured T cells have a central memory-like
phenotype defined by the expression of cell surface markers
CD45RO and CD62L [35] [in FACS analysis these populations
are defined as follows; CD45RO+/CD62L2 (Tem), CD45RO+/
CD62L+ (Tcm) or CD45RO
low/CD62L+ (Tn), and CD45RO2/
CD62L2 (TemRA, effector-memory CD45RA+)]. To determine
the lytic potential of these in vitro generated CD8+ T cells, we
utilized T cells genetically engineered with an anti-MART-1 TCR
as effector cells and melanoma lines as target cells. In this model,
lytic potential is measured by the cell surface expression of the
degranulation marker CD107a [31]. CD107a is lysosomal-
associated membrane protein 1 (LAMP1), and it is a component
of lysosomal-associated vesicles that contain granzyme B and
perforin [31].
When MART-1 TCR engineered effector T cells were co-
cultured with HLA-matched melanoma cell lines 526 and 624
antigen-specific loss of CD62L expression was observed in the
Tcm quadrant (figure 1A, left column). We next looked for the
expression of CD107a in the different T cell populations (figure 1A,
histograms). CD107a formation was readily observed in the
CD62L2 populations of effector memory (Tem) and effector
memory CD45RA+ (TemRA); but was minimal expressed in the
CD62L+ populations of central memory (Tcm) and naı ¨ve cells
(Tn). As expected, CD107a expression was not observed in T cells
not exposed to targets or exposed to the HLA mismatched tumor
line 938 (figure 1). This was a reproducible finding and statistically
significant (Figure 1B, p,0.001).
To confirm that this observation was tumor-antigen specific, the
experiment was repeated with an additional PBL donor and
analysis of marker gene expression further refined by gating on
MART-1 TCR gene-engineered cells (Figure 2). By gating on
CD3/CD8/MART-1+ T cells following co-culture, we detected a
more pronounced loss of CD62L expression compared to MART-
1 tetramer negative cells (Figure 2A, compare 1
st and 2
nd
columns). We observed a concomitant increase in CD107a
formation in the MART-1 TCR+ population upon co-culture
with MART-1+/HLA matched tumor lines (Figure 2A, compare
3
rd and 4
th columns). Again the expression of CD107a is primarily
observed in the Tem population. These observations were
repeated in two additional donors (data not shown). To determine
the relation of CD107a and CD62L on a per cell basis, co-cultured
cells were also analyzed and presented as dot plots (Figure 2B).
Consistent with figure 1, we observed the expression of CD107a
predominantly in the CD62L null population. Furthermore, the
expression of CD107a was inversely correlated with the cell
surface expression of CD62L (Figure 2B).
The loss of CD62L is due to antigen induced shedding
from T cells
MART-1 TCR transduced T cells were sorted for the CD8+
Tcm population and then co-cultured with melanoma lines for 4 h
(Figure 3). At the completion of the co-culture, the phenotype of
the cells was determined and we again observed the loss of CD62L
expression from the Tcm cells only in the co-culture with MHC
matched tumor line 526. The shedding of CD62L from T cells
following mitogen stimulation is well studied [7,42]. To determine
if the loss of CD62L expression on these TCR gene–engineered T
cells was similarly caused by shedding, we assayed for the presence
of CD62L in both total cell lysates and in cell culture media. As
measured by ELISA, we found there was a reduced level of
CD62L in total cell lysates in the MHC matched 526 group, with
a concomitant increased level of soluble CD62L in the cell culture
media from the same group (Figure 3, bottom), suggesting that
CD62L is actively shed into the culture upon antigen encounter.
To determine the dynamics of this shedding process, we repeated
the co-culture of the sorted CD8+ Tcm enriched population with
melanoma cells and found that shedding was detected as early as
1 h after encountering tumor antigen (Figure 4A). Moreover, we
could detect the shedding as early as 15 min after tumor antigen
encounter (data not shown). The shedding progressed over time
and within 4–6 h, shedding reached its peak (Figure 4A). In
another independent experiment, we confirmed the dynamics of
CD62L over time, and again observed the concomitant increase of
surface CD107a expression following the shedding of CD62L
(Figure 4B).
Introduction of CD62L shedding resistant mutants
downgrades T cell anti-tumor activity
The shedding of CD62L from T cells is an active process
mediated by a membrane bound protease, ADAM17. We
prepared lentiviral vectors harboring human wild type CD62L
and a shedding resistant mutant of CD62L, dK-S (a 7 amino acid
deletion covering K280-S286) [4]. CTL line JKF6 is a long-term
cultured, anti-MART-1 reactive tumor infiltrating lymphocyte
(TIL) that does not express CD62L. We transduced JKF6 with
lentiviral vectors expressing the wild type CD62L and the dK-S
mutant, and selected these cells for uniform CD62L expression
(Figure 5A). The purified JKF6 cells constitutively expressing wild
type CD62L and its mutant were then co-cultured with melanoma
lines.
Following co-culture, transduced cells were analyzed using
CD45RO and CD62L, and similar to our observations with PBL,
we observed a loss of CD62L expression (presumptively by
shedding) following co-culture of the wild-type CD62L gene-
engineered JKF6 cell line with HLA matched melanoma lines
A New Role for CD62L in T Cells
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22560Figure 1. The loss of CD62L is specific and correlates with CD107a surface expression. A. MART-1 TCR vector-transduced T cells were co-
cultured with melanoma lines 526, 624 (both HLA-A*0201 positive) and 938 (HLA-A*0201 negative) for four hours and then analyzed by FACS. The
first column on left, the cells were plotted using differentiation markers CD45RO and CD62L into 4 subsets, the expression of CD107a on each subset
was denoted in the histograms to the right. B. Based on data from three independent experiments, the expression of CD107a after co-culture with
melanoma lines was determined and mean% 6 stdev plotted. Student t-test was used for statistical analysis. The fluorophore conjugated antibodies
used in this analysis were CD107a FITC, CD62L PE, CD45RO APC, CD3 APC-Cy7 with propidium iodide staining.
doi:10.1371/journal.pone.0022560.g001
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JKF6 cells expressing the CD62L shedding resistant mutant dK-S
(Figure 5B). As we observed in PBL, the detection of CD107a was
inversely related to the shedding of CD62L (Figure 5B, histograms
on right). We observed an increase of CD107a in the cells
engineered with the wild-type CD62L, while there was reduced
CD107a formation in JKF6 cells engineered with the shedding
resistant mutant (Figure 5B). Overall, there was approximately a
50% reduction in the CD107a surface expression (p,0.01) in
JKF6 cells engineered with the dK-S mutant CD62L gene
(Figure 5C). To determine whether the reduction in CD107a
formation was linked to the ability of JKF6 to lyse melanoma cells,
the engineered cells were assayed in a standard 4 h 51Cr-release
assay (Figure 5D). Results of this experiment demonstrate that the
lytic activity of the JKF6 cells expressing the shedding resistant
mutant dK-S was significantly downgraded (p,0.05) compared to
cells engineered with the wild-type CD62L or mock transduced
cells.
To determine if the link between CD62L expression and
CD107a mobilization was dependent on TCR-HLA-A2 interac-
tions, we bypassed this antigen-specific activation using PMA/
Ionomycin (Figure 6). When the engineered JKF6 cells were non-
Figure 2. The loss of CD62L is tumor antigen specific and the expression of CD107a occurs on CD62L negative cells. A. TCR
transduced cells were cultured as described in methods. Shown is the FACS analysis, where cells were gated on CD3/CD8/MART-1+ or CD3/CD8/
MART-12, and then plotted using markers CD45RO and CD62L (left two column plots). The expression of CD107a on each group was then
determined and separately plotted in the histograms on right corresponding to column data on left. In each histogram the expression of CD107a on
each subset was overlaid reflecting Tem, Tcm and naı ¨ve populations. Red (CD45RO+CD62L2) indicates Tem, blue (CD45RO+CD62L+) indicates Tcm,
and green (CD45RO2CD62L+) indicates Tn population. B. The cells were processed as described above. By FACS analysis, the cells were gated on
CD3/CD8/MART-1+ or CD3/CD8/MART-12, then plotted using markers CD107a and CD62L in dot plots. The fluorophore conjugated antibodies used
in this analysis were CD107a FITC, CD62L PE, CD45RO APC, CD3 APC-Cy7 with propidium iodide staining.
doi:10.1371/journal.pone.0022560.g002
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ability of cells to express CD107a on the cell surface if they were
engineered with the shedding resistant dK-S mutant CD62L gene
(28.8%) compared to mock-transduced (66.2%) and wild-type
(54.1%) engineered cells (Figure 6A). This observation was not due
to a lack of the ability for PMA/Ionomycin to stimulate these cells,
as production of the effector cytokine IFN-c was not affected
(Figure 6A). The overall reduction in CD107a surface expression
was about 70% compared to mock-transduced and wild type
CD62L engineered cells and this was statistically significant
(Figure 6B).
Discussion
The CD62L knockout mouse model indicates that CD62L plays
an essential role in lymphocyte homing to lymphoid tissues and
sites of inflammation, and that CD62L shedding from antigen-
activated T cells prevents their reentry into peripheral lymph
nodes [7]. However, transgenic mice expressing cleavage-resistant
CD62L mutants delay, but do not negate effective immune
response to viral infections [9], suggesting that lymphocyte
trafficking is only part of a successful anti-viral response. It has
been reported that the shedding of CD62L is primarily mediated
by the metalloprotease ADAM17. Many leukocytes express
ADAM17, and a number of ADAM17 substrates are immuno-
logically important proteins including; TNF-a, its receptors
TNFRI and TNFRII, and CD62L [6,43]. CD62L is also present
at relatively high levels in the serum of normal individuals, and it
has been postulated that this may direct leucocytes to sites of
inflammation [44]. Our data suggest CD62L is not simply a
homing molecule, rather its’ shedding after activation may play a
novel role in determining the acquisition of lytic function as
measured by the cell surface expression of CD107a, a marker of T
cell degranulation [21,30,31,32].
In this study, we generated an in vitro model illustrating the
dynamics of CD62L expression on human cytotoxic T lympho-
cytes following encounter with tumor antigen. CD62L shedding
was initiated within minutes after CTL encounter with tumor
antigen and reached its maximum level at 4–6 h post-activation,
consistent with reports for murine T cells [42]. CD62L shedding is
not limited to T cells but is also found in cells of the innate
immune system. In resting neutrophils, CD62L is constitutively
expressed at high levels, and essentially all molecules are shed
within minutes following neutrophil activation [45]. The differ-
ence in the rate of shedding between T cells and neutrophils might
represent the activity of ADAM17 on their surfaces, or their sites
of activation. While T cell activation occurs within the lymph
node, the activation of neutrophils (which is not antigen-specific)
occurs rapidly at sites of infection, which presumptively facilitates
the eradication of pathogens. However, the activation of T cells (a
member of the adaptive immune system) occurs more slowly via
antigen presenting cells (APC) within lymph nodes. The slow
Figure 3. The loss of CD62L is due to antigen induced shedding in T cells. Top. MART-1 TCR transduced cells were gated on the CD8+ and
CD45RO+/CD62L+ (Tcm) population and sorted by FACS. The sorted Tcm cells were co-cultured with melanoma lines for 4 h. Culture media
(supernatant) was collected and the cells stained for FACS analysis. Shown in the top plots is the expression of CD45RO and CD62L in unmanipulated
Tcm cells, Tcm cells cultured with melanoma line 938 (HLA-A02012), and Tcm cells cultured with melanoma line 526 (HLA-A0201+). The numbers in
each quadrant represent the percent of cells in that quadrant. The fluorophore conjugated antibodies used in this analysis were CD107a FITC, CD62L
PE, CD45RO APC, CD3 APC-Cy7 with propidium iodide staining. Bottom. The amount of CD62L in the cell media supernatant and total cell lysates
was measured by ELISA. The amount of CD62L in the total cellular lysate in the Tcm group was set as 100% for comparison to the other lysate values
(left side bars). For the cell supernatant determinations, the amount of soluble CD62L in the supernatant from the Tcm+526 group was set as 100%,
for comparison to other values (right side bars). Data shown are the normalized values 6 stdev for three independent determinations.
doi:10.1371/journal.pone.0022560.g003
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protective factor for lymphoid tissues, by allowing activated T cells
to migrate out of the lymph nodes as they become fully activated.
Our data support this hypothesis in that the surface of CD107a
occurred only in T cells after shedding of CD62L.
Since the putative primary cleavage site (K283-S284) of human
CD62L was identified, we cloned wild type and a shedding resistant
mutant dK-S [4] into lentiviral vectors to directly test for an
association between CD62L and CD107a. In all of our assays, the
dK-S mutant was almost completely resistant to activation induced
shedding. The cytoplasmic tail of CD62L is highly basic and consists
of only 17 amino acids that have been reported to regulate shedding,
microvillus positioning and the tethering/rolling [46]. Specifically,
the cytoplasmic tail of CD62L has been reported to interact with at
least three different proteins [47] including calmodulin, a-actinin (a
member of the ezrin/radixin/moesin (ERM) family of membrane-
cytoskeleton cross-linkers), and protein kinase C isoenzymes.
Disruption of these interactions may reduce the shedding [48] or
inhibit tethering/rolling efficiencies in vitro [49].
In this study, we found the shedding of CD62L from the surface of T
cells was antigen specific, and CD107a surface expression could only
be detected in cells that had shed CD62L. Moreover, when we
introduced a shedding resistant mutant of CD62L into T cells, this not
only blocked CD62L shedding but also affected the surface expression
of CD107a and this correlated with a downgraded ability of these cells
to lyse targets. Thus our data suggest that there is a link between the
shedding of CD62L and the acquisition of T cell lytic ability. As the
cytoplasmic tail of CD62L interacts with molecules such as a-actinin,
and a-actinin can interact with the cytoskeleton, we hypothesize that
the abolishment of CD62L shedding from the T cell surface could
ultimately affect the cytoskeleton structure, which in turn may disrupt
the mobilization of cytotoxic granules to the cell surface (which is
measured by the surrogate maker CD107a) and release of perforin and
granzyme B to initiate target cell lysis.
It is interesting to note that, in the case of ex vivo cultured murine
lymphocytes used for adoptive immunotherapy to treat B16
melanoma, extended culture periods result in loss of CD62L
expression and this is correlated with decreased effectiveness in
vivo[50]. This observation has been used to support the hypothesis
that terminally differentiated T cells are less effective anti-cancer
cells [50]. Our date would further suggest a potential biochemical
link between the loss of CD62L and decreased effector functions.
Clearly the immune system maintains a balance between T cell
homingto sitesofinfection/inflammationandeffectorfunction,and
our data suggest that one of the main trafficking molecules, CD62L,
may also be involved with the acquisition of effector cell function.
Figure 4. The dynamics of CD62L shedding is inversely correlated with the expression of CD107a. A. The dynamics of CD62L shedding
in CD8+/CD62L+ population was followed over 6hr. CD8+ MART-1 TCR transduced Tcm cells were sorted by FACS as in figure 3. These sorted cells
(CD45RO+/CD62L+) were co-cultured with melanoma lines 526 (HLA-A0201+) and 938 (HLA-A02012) for the times indicated and analyzed for
CD45RO and CD62L. Column on left (co-cultured with 938) and on right (co-cultured with 526). The numbers in each quadrant represent the percent
of cells in that quadrant. B. The expression of CD107a correlates with the shedding of CD62L in CD8+/CD62L+ population. CD8+ MART-1 TCR
transduced T cells from a different donor were co-cultures as described in methods. The cells were gated on CD3/CD8/MART-1+ and then plotted for
CD107a and CD62L expression. The samples were collected and stained at the times indicated on right. The fluorophores conjugated antibodies for
this analysis were CD107a FITC, MART-1 PE, CD62L APC, CD45RO PE-Cy7, CD8 APC-Cy7 and propidium iodide staining.
doi:10.1371/journal.pone.0022560.g004
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PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22560Figure 5. Introduction of shedding resistant CD62L affects the surface expression of CD107a. A. TIL line JKF6 was transduced with
lentiviral vector harboring human CD62L and its shedding resistant mutant dK-S. JKF6 cells expressing CD62L and the dK-S mutant were enriched
using CD62L beads and analyzed for CD62L expression by FACS. B. JKF6 gene engineered cell lines were co-cultured with melanoma lines 526 (HLA-
A0201+) and 938 (HLA-A02012) analyzed for CD45RO and CD62L expression (Mock, mock transduced cells; WT, CD62L transduced JKF6; dK-S, JKF6
transduced with shedding resistant mutant). On left, FACS plots from co-cultures of different groups; on right, overlayed histograms of the expression
of CD107a in Tem and Tcm subsets. Solid line (CD45RO+CD62L2) indicates Tem, semi-solid line (CD45RO+CD62L+) indicates Tcm. C. Quantification
of CD107a expression from triplicate determinations was calculated and plotted as % CD107a+ (mean 6 STDEV). Statistical analysis using t test; *: dK-
S vs mock and WT, p,0.01. D. The lytic activity of JKF6 lines expressing CD62L and its mutant were determined by co-culture with
51Cr-labeled
melanoma lines at the indicated ratios. The percent cell lysis was calculated using the formula ((specific release-spontaneous release)/(total release-
spontaneous release))6100. Results representing mean of triplicate cultures were plotted. *: dK-S vs WT, p,0.05; #: dK-S vs Mock, p,0.05. The t-Test
with two samples assuming equal variances was used for statistical analysis. The fluorophores conjugated antibodies for this analysis were CD107a
FITC, MART-1 PE, CD62L APC, CD45RO PE-Cy7, CD8 APC-Cy7 and propidium iodide staining.
doi:10.1371/journal.pone.0022560.g005
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Figure 6. Introduction of shedding resistant CD62L into JKF6 hinders CD107a expression following non-specific activation. A. JKF6
lines expressing CD62L and mutant dK-S were activated using PMA/Ionomycin (PMA/Ion) for 4 h, and the surface expression for CD107a and IFN-c
was evaluated by FACS. One representative result from three independent experiments is shown (Mock, mock transduced cells; WT, CD62L
transduced JKF6; dK-S, JKF6 transduced with shedding resistant mutant). For CD107a live cell staining, the fluorophores conjugated antibodies were
CD107a FITC, CD62L APC, CD3 PE and propidium iodide staining; For intracellular staining of IFN-c, the fluorophore conjugated antibodies were IFN-c
FITC, CD62L APC, CD3 PE, without propidium iodide staining. B. Plot of the percent positive cells for CD107a and IFN-c on the surface of JKF6 lines
expressing wild type and shedding resistant CD62L mutant. The mean 6 STDEV from three independent experiments is displayed, and t-test was
used for statistical analysis.
doi:10.1371/journal.pone.0022560.g006
A New Role for CD62L in T Cells
PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22560References
1. Pavalko FM, Walker DM, Graham L, Goheen M, Doerschuk CM, et al. (1995)
The cytoplasmic domain of L-selectin interacts with cytoskeletal proteins via
alpha-actinin: receptor positioning in microvilli does not require interaction with
alpha-actinin. J Cell Biol 129: 1155–1164.
2. Ley K, Kansas GS (2004) Selectins in T-cell recruitment to non-lymphoid tissues
and sites of inflammation. Nat Rev Immunol 4: 325–335.
3. Ley K, Laudanna C, Cybulsky MI, Nourshargh S (2007) Getting to the site of
inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7:
678–689.
4. Chen A, Engel P, Tedder TF (1995) Structural requirements regulate
endoproteolytic release of the L-selectin (CD62L) adhesion receptor from the
cell surface of leukocytes. J Exp Med 182: 519–530.
5. Kahn J, Ingraham RH, Shirley F, Migaki GI, Kishimoto TK (1994) Membrane
proximal cleavage of L-selectin: identification of the cleavage site and a 6-kD
transmembrane peptide fragment of L-selectin. J Cell Biol 125: 461–470.
6. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, et al. (1998) An
essential role for ectodomain shedding in mammalian development. Science 282:
1281–1284.
7. Galkina E, Tanousis K, Preece G, Tolaini M, Kioussis D, et al. (2003) L-selectin
shedding does not regulate constitutive T cell trafficking but controls the
migration pathways of antigen-activated T lymphocytes. J Exp Med 198:
1323–1335.
8. Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, et al. (1994)
Lymphocyte homing and leukocyte rolling and migration are impaired in L-
selectin-deficient mice. Immunity 1: 247–260.
9. Richards H, Longhi MP, Wright K, Gallimore A, Ager A (2008) CD62L (L-
selectin) down-regulation does not affect memory T cell distribution but failure
to shed compromises anti-viral immunity. J Immunol 180: 198–206.
10. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of
memory T lymphocytes with distinct homing potentials and effector functions.
Nature 401: 708–712.
11. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector
memory T cell subsets: function, generation, and maintenance. Annu Rev
Immunol 22: 745–763.
12. Campbell JJ, Bowman EP, Murphy K, Youngman KR, Siani MA, et al. (1998)
6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high
endothelium, is an agonist for the MIP-3beta receptor CCR7. J Cell Biol 141:
1053–1059.
13. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, et al. (1999)
CCR7 coordinates the primary immune response by establishing functional
microenvironments in secondary lymphoid organs. Cell 99: 23–33.
14. Unsoeld H, Pircher H (2005) Complex memory T-cell phenotypes revealed by
coexpression of CD62L and CCR7. J Virol 79: 4510–4513.
15. Tomiyama H, Takata H, Matsuda T, Takiguchi M (2004) Phenotypic
classification of human CD8+ T cells reflecting their function: inverse
correlation between quantitative expression of CD27 and cytotoxic effector
function. Eur J Immunol 34: 999–1010.
16. Baars PA, Sierro S, Arens R, Tesselaar K, Hooibrink B, et al. (2005) Properties
of murine (CD8+)CD272 T cells. Eur J Immunol 35: 3131–3141.
17. de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, et al. (2005)
Selective accumulation of differentiated CD8+ T cells specific for respiratory
viruses in the human lung. J Exp Med 202: 1433–1442.
18. Mora JR, von Andrian UH (2006) T-cell homing specificity and plasticity: new
concepts and future challenges. Trends Immunol 27: 235–243.
19. Lefrancois L (2006) Development, trafficking, and function of memory T-cell
subsets. Immunol Rev 211: 93–103.
20. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, et al. (2008) Adoptive
transfer of effector CD8+ T cells derived from central memory cells establishes
persistent T cell memory in primates. J Clin Invest 118: 294–305.
21. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, et al.
(2005) Central memory self/tumor-reactive CD8+ T cells confer superior
antitumor immunity compared with effector memory T cells. Proc Natl Acad
Sci U S A 102: 9571–9576.
22. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. (2003)
Lineage relationship and protective immunity of memory CD8 T cell subsets.
Nat Immunol 4: 225–234.
23. Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, et al. (2005) Initial
T cell frequency dictates memory CD8+ T cell lineage commitment. Nat
Immunol 6: 793–799.
24. Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, et al. (1997)
Phenotypic and functional separation of memory and effector human CD8+ T
cells. J Exp Med 186: 1407–1418.
25. Masopust D, Vezys V, Marzo AL, Lefrancois L (2001) Preferential localization
of effector memory cells in nonlymphoid tissue. Science 291: 2413–2417.
26. Blott EJ, Griffiths GM (2002) Secretory lysosomes. Nat Rev Mol Cell Biol 3:
122–131.
27. Kannan K, Stewart RM, Bounds W, Carlsson SR, Fukuda M, et al. (1996)
Lysosome-associated membrane proteins h-LAMP1 (CD107a) and h-LAMP2
(CD107b) are activation-dependent cell surface glycoproteins in human
peripheral blood mononuclear cells which mediate cell adhesion to vascular
endothelium. Cell Immunol 171: 10–19.
28. de Saint Basile G, Menasche G, Fischer A (2010) Molecular mechanisms of
biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 10: 568–579.
29. Lettau M, Schmidt H, Kabelitz D, Janssen O (2007) Secretory lysosomes and
their cargo in T and NK cells. Immunol Lett 108: 10–19.
30. Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G (2009) Relationship
between CD107a expression and cytotoxic activity. Cell Immunol 254: 149–154.
31. Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the
identification of natural killer cell activity. J Immunol Methods 294: 15–22.
32. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003)
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow
cytometric assay for degranulation. J Immunol Methods 281: 65–78.
33. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, et al. (2009) Gene
therapy with human and mouse T-cell receptors mediates cancer regression and
targets normal tissues expressing cognate antigen. Blood 114: 535–546.
34. Yang S, Rosenberg SA, Morgan RA (2008) Clinical-scale lentiviral vector
transduction of PBL for TCR gene therapy and potential for expression in less-
differentiated cells. J Immunother 31: 830–839.
35. Yang S, Dudley ME, Rosenberg SA, Morgan RA (2010) A simplified method for
the clinical-scale generation of central memory-like CD8+ T cells after
transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.
J Immunother 33: 648–658.
36. Jones S, Peng PD, Yang S, Hsu C, Cohen CJ, et al. (2009) Lentiviral vector
design for optimal TCR gene expression in the transduction of PBL and TIL.
Hum Gene Ther.
37. Schambach A, Bohne J, Baum C, Hermann FG, Egerer L, et al. (2006)
Woodchuck hepatitis virus post-transcriptional regulatory element deleted from
X protein and promoter sequences enhances retroviral vector titer and
expression. Gene Ther 13: 641–645.
38. Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, et al. (2008) Development of
optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression
and robust tumor cell recognition. Gene Ther 15: 1411–1423.
39. Jones S, Peng PD, Yang S, Hsu C, Cohen CJ, et al. (2009) Lentiviral vector
design for optimal T cell receptor gene expression in the transduction of
peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Hum Gene
Ther 20: 630–640.
40. Yang S, Dudley ME, Rosenberg SA, Morgan RA (2010) A simplified method for
the clinical-scale generation of central memory-like CD8+ T cells after
transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.
J Immunother 33: 648–658.
41. Topalian SL, Solomon D, Rosenberg SA (1989) Tumor-specific cytolysis by
lymphocytes infiltrating human melanomas. J Immunol 142: 3714–3725.
42. Chao CC, Jensen R, Dailey MO (1997) Mechanisms of L-selectin regulation by
activated T cells. J Immunol 159: 1686–1694.
43. Garton KJ, Gough PJ, Raines EW (2006) Emerging roles for ectodomain
shedding in the regulation of inflammatory responses. J Leukoc Biol 79:
1105–1116.
44. Wang Y, Zhang AC, Ni Z, Herrera A, Walcheck B (2010) ADAM17 activity and
other mechanisms of soluble L-selectin production during death receptor-
induced leukocyte apoptosis. J Immunol 184: 4447–4454.
45. Kishimoto TK, Jutila MA, Berg EL, Butcher EC (1989) Neutrophil Mac-1 and
MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science
245: 1238–1241.
46. Ivetic A, Ridley AJ (2004) The telling tail of L-selectin. Biochem Soc Trans 32:
1118–1121.
47. Killock DJ, Parsons M, Zarrouk M, Ameer-Beg SM, Ridley AJ, et al. (2009) In
Vitro and in Vivo Characterization of Molecular Interactions between
Calmodulin, Ezrin/Radixin/Moesin, and L-selectin. J Biol Chem 284:
8833–8845.
48. Diaz-Rodriguez E, Esparis-Ogando A, Montero JC, Yuste L, Pandiella A (2000)
Stimulation of cleavage of membrane proteins by calmodulin inhibitors.
Biochem J 346 Pt 2: 359–367.
49. Dwir O, Kansas GS, Alon R (2001) Cytoplasmic anchorage of L-selectin
controls leukocyte capture and rolling by increasing the mechanical stability of
the selectin tether. J Cell Biol 155: 145–156.
50. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005)
Acquisition of full effector function in vitro paradoxically impairs the in vivo
antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115:
1616–1626.
A New Role for CD62L in T Cells
PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e22560